Yingsi Intelligent's stock price surged 14.95% during the trading session

1、 A heavyweight cooperation worth 2.75 billion US dollars has landed, and Lilly has obtained exclusive rights to GLP-1 hypoglycemic drugs

According to the announcement from both parties, Eli Lilly and Innolux have reached a drug discovery and pipeline authorization cooperation. According to the agreement, Lilly will acquire the exclusive global development, production, and commercialization rights of a GLP-1 hypoglycemic drug developed by Insilicon Intelligence using its AI technology.

In terms of transaction amount, Yingsi Intelligent will receive a total potential revenue of up to 2.75 billion US dollars, including a down payment of 115 million US dollars, and receive further payments after reaching development, regulatory, and commercialization milestones. In addition, the company will also receive tiered royalties based on the future global sales of the drug. This grand collaboration fully demonstrates Lilly's high confidence in the potential of the pipeline and the research and development capabilities of Yingsi Intelligent AI.

2、 Deepening Cooperation: From AI Platform to Pipeline Authorization, Three Year and Three Level Leap

This cooperation was not achieved overnight, but rather a continuous deepening of the partnership between the two parties since 2023

In 2023, the two parties reached a software licensing cooperation based on the Pharma.AI platform of British Silicon Intelligence, and Lilly began to trial its AI technology.

November 2025: The cooperation will be upgraded to a strategic cooperation in drug development, focusing on the generation and optimization of candidate compounds around designated targets.

December 2025: Lilly participates in the cornerstone investment of the British Silicon Intelligent Hong Kong Stock IPO, subscribing $5 million to demonstrate long-term strategic synergy.

March 2026: This global exclusive pipeline authorization of up to 2.75 billion US dollars will take cooperation to new heights.

3、 The market response is enthusiastic, and the commercial value of AI pharmaceuticals has been verified

Stimulated by this positive news, the stock price of Yingsi Intelligent quickly strengthened in the morning session of March 30th, with an intraday increase of over 14% and active market trading. Industry analysis believes that this collaboration is a landmark event in the field of AI pharmaceuticals, demonstrating the commercial value and potential of AI technology in accelerating innovative drug development, especially in core areas such as metabolic diseases.

For Lilly, this collaboration further strengthens its pipeline layout in the GLP-1 field and is expected to leverage AI to develop more competitive oral therapies. For Yingsi Intelligence, this transaction will significantly enhance its cash flow and provide strong demonstration and support for the commercialization of its AI pharmaceutical platform.